U.S. Traders May Be Accidentally Buying This Biotech Stock – But It May Be Worth Owning Anyways!

Shares of the biotech highlighted in today’s article have soared this year, but is this performance due to factors such as the COVID-19 drug the firm is developing and a planned spinoff of its diagnostic tool for predicting breast cancer – or is it due to traders being mistaken by the firm’s U.S. ticker symbol? For why U.S. traders may be accidentally buying shares of this biotech firm – and why the stock may be worth owning nonetheless – CLICK HERE.